BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer. 2000;82:812-817. [PMID: 10732751 DOI: 10.1054/bjoc.1999.1004] [Cited by in Crossref: 245] [Cited by in F6Publishing: 208] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Amato RJ. Thalidomide therapy for renal cell carcinoma. Critical Reviews in Oncology/Hematology 2003;46:59-65. [DOI: 10.1016/s1040-8428(03)00065-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
2 Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol 2005;125:201-6. [PMID: 16098027 DOI: 10.1111/j.0022-202X.2005.23830.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Schwartz LH, Mazumdar M, Wang L, Smith A, Marion S, Panicek DM, Motzer RJ. Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials: Effect of measurement criteria and other parameters. Cancer 2003;98:1611-9. [DOI: 10.1002/cncr.11712] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
4 Olencki T, Malhi S, Mekhail T, Dreicer R, Elson P, Wood L, Bukowski RM. Phase I trial of thalidomide and Interleukin-2 in patients with metastatic renal cell carcinoma. Invest New Drugs 2006;24:321-6. [DOI: 10.1007/s10637-005-5211-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
5 Granato AM, Frassineti GL, Giovannini N, Ballardini M, Nanni O, Maltoni R, Amadori D, Volpi A. Do serum angiogenic growth factors provide additional information to that of conventional markers in monitoring the course of metastatic breast cancer? Tumour Biol 2006;27:302-8. [PMID: 17028465 DOI: 10.1159/000096072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
6 Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R. Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in Oncology 2003;30:270-4. [DOI: 10.1053/sonc.2003.50044] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
7 El-Aarag BY, Kasai T, Zahran MA, Zakhary NI, Shigehiro T, Sekhar SC, Agwa HS, Mizutani A, Murakami H, Kakuta H, Seno M. In vitro anti-proliferative and anti-angiogenic activities of thalidomide dithiocarbamate analogs. Int Immunopharmacol 2014;21:283-92. [PMID: 24859059 DOI: 10.1016/j.intimp.2014.05.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
8 Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000;89:1181-94. [DOI: 10.1002/1097-0142(20000915)89:6<1181::aid-cncr1>3.0.co;2-t] [Cited by in Crossref: 69] [Article Influence: 3.1] [Reference Citation Analysis]
9 Agarwal R, Linch M, Kaye SB. Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol 2006;32:875-86. [PMID: 16704916 DOI: 10.1016/j.ejso.2006.03.041] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
10 Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 2009;17:278-84. [PMID: 19050699 DOI: 10.1038/mt.2008.258] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
11 Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol. 2004;22:454-463. [PMID: 14752067 DOI: 10.1200/jco.2004.06.132] [Cited by in Crossref: 582] [Cited by in F6Publishing: 182] [Article Influence: 32.3] [Reference Citation Analysis]
12 Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer. 2006;42:793-802. [PMID: 16524718 DOI: 10.1016/j.ejca.2006.01.013] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 3.9] [Reference Citation Analysis]
13 Vasvari GP, Dyckhoff G, Kashfi F, Lemke B, Lohr J, Helmke BM, Schirrmacher V, Plinkert PK, Beckhove P, Herold-mende CC. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activityin vitro andin vivo. Int J Cancer 2007;121:1697-704. [DOI: 10.1002/ijc.22867] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
14 Zhou S, Kestell P, Tingle MD, Paxton JW. Thalidomide in Cancer Treatment: A Potential Role in the Elderly? Drugs & Aging 2002;19:85-100. [DOI: 10.2165/00002512-200219020-00002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
15 Olgen S, Kotra LP. Drug Repurposing in the Development of Anticancer Agents. Curr Med Chem 2019;26:5410-27. [PMID: 30009698 DOI: 10.2174/0929867325666180713155702] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
16 Srinivas S, Guardino AE. A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU Int 2005;96:536-9. [DOI: 10.1111/j.1464-410x.2005.05680.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Farley JH, Birrer MJ. Biologic directed therapies in gynecologic oncology. Curr Oncol Rep 2003;5:459-67. [PMID: 14521804 DOI: 10.1007/s11912-003-0006-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Guppy A, Nathan P, Rustin G. Epithelial Ovarian Cancer: A Review of Current Management. Clinical Oncology 2005;17:399-411. [DOI: 10.1016/j.clon.2005.05.009] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 4.3] [Reference Citation Analysis]
19 Amato RJ, Malya R, Rawat A. Phase II Study of Combination Thalidomide/Interleukin-2 Therapy Plus Granulocyte Macrophage-Colony Stimulating Factor in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology 2008;31:237-43. [DOI: 10.1097/coc.0b013e31815e4505] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
20 Rasila KK, Burger RA, Smith H, Lee FC, Verschrae-gen C. Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets. Int J Gynecol Cancer. 2005;15:710-726. [PMID: 16174217 DOI: 10.1111/j.1525-1438.2005.00132.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
21 Romiti A, Cox MC, Sarcina I, Di Rocco R, D’Antonio C, Barucca V, Marchetti P. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol. 2013;72:13-33. [PMID: 23475105 DOI: 10.1007/s00280-013-2125-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 6.4] [Reference Citation Analysis]
22 Cohen EE, Vokes EE. Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer”. Clinical Lung Cancer 2000;2:53-4. [DOI: 10.1016/s1525-7304(11)70622-2] [Reference Citation Analysis]
23 Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 2011;68:1119-24. [PMID: 21373895 DOI: 10.1007/s00280-011-1580-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
24 Reed MJ, Karres N, Eyman D, Cruz A, Brekken RA, Plymate S. The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. Int J Cancer 2007;120:753-60. [PMID: 17131319 DOI: 10.1002/ijc.22351] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
25 Figg WD, Kruger EA, Price DK, Kim S, Dahut WD. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002;20:183-94. [PMID: 12099578 DOI: 10.1023/a:1015626410273] [Cited by in Crossref: 69] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
26 Myoung H, Hong SD, Kim YY, Hong SP, Kim MJ. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett. 2001;163:191-200. [PMID: 11165754 DOI: 10.1016/s0304-3835(00)00701-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
27 Adeniran AJ, Al-Ahmadie H, Iyengar P, Reuter VE, Lin O. Fine needle aspiration of renal cortical lesions in adults. Diagn Cytopathol 2010;38:710-5. [PMID: 19950394 DOI: 10.1002/dc.21274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 2009;73:337-41. [PMID: 18950837 DOI: 10.1016/j.urology.2008.08.476] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
29 Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2009;101:1049-57. [PMID: 19608997 DOI: 10.1093/jnci/djp200] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 6.5] [Reference Citation Analysis]
30 Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment: . Current Opinion in Oncology 2000;12:564-73. [DOI: 10.1097/00001622-200011000-00009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
31 Kieran MW, Billett A. ANTIANGIOGENESIS THERAPY. Hematology/Oncology Clinics of North America 2001;15:835-52. [DOI: 10.1016/s0889-8588(05)70254-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
32 Celorio A, Armas A. Angiogénesis en los tumores epiteliales ováricos. Clínica e Investigación en Ginecología y Obstetricia 2001;28:183-96. [DOI: 10.1016/s0210-573x(01)77090-6] [Reference Citation Analysis]
33 O'Byrne KJ, Steward WP. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. Expert Opin Emerg Drugs 2001;6:155-74. [PMID: 15989502 DOI: 10.1517/14728214.6.1.155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Yau T, Chan P, Wong H, Ng KK, Chok S, Cheung T, Lam V, Epstein RJ, Fan S, Poon RT. Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 2007;72:67-71. [DOI: 10.1159/000111709] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
35 Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol. 2005;23:1295-1311. [PMID: 15718328 DOI: 10.1200/jco.2005.10.022] [Cited by in Crossref: 150] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
36 Coleman M, Leonard J, Lyons L, Pekle K, Nahum K, Pearse R, Niesvizky R, Michaeli J. BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia. Leukemia & Lymphoma 2009;43:1777-82. [DOI: 10.1080/1042819021000006303] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
37 Stepień H, Lawnicka H, Mucha S, Wagrowska-Danilewicz M, Stepień B, Siejka A, Komorowski J. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats. Life Sci 2006;79:1741-8. [PMID: 16846617 DOI: 10.1016/j.lfs.2006.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Ng S, Brown M, Figg W. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomedicine & Pharmacotherapy 2002;56:194-9. [DOI: 10.1016/s0753-3322(02)00177-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
39 Shah RN, Ahmad T, Eisen TG. Treatment of recurrent or metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2004;4:1069-80. [PMID: 15606334 DOI: 10.1586/14737140.4.6.1069] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Amato RJ, Morgan M, Rawat A. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma. Cancer 2006;106:1498-506. [DOI: 10.1002/cncr.21737] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
41 Chanan-khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005;106:3348-52. [DOI: 10.1182/blood-2005-02-0669] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
42 Tarhini AA, Agarwala SS. Novel agents in development for the treatment of melanoma. Expert Opinion on Investigational Drugs 2005;14:885-92. [DOI: 10.1517/13543784.14.7.885] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
43 Logan TF. The systemic treatment of advanced cutaneous melanoma. Facial Plast Surg Clin North Am 2003;11:75-85. [PMID: 15062290 DOI: 10.1016/S1064-7406(02)00056-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Gasparini G. Metronomic scheduling: the future of chemotherapy? The Lancet Oncology 2001;2:733-40. [DOI: 10.1016/s1470-2045(01)00587-3] [Cited by in Crossref: 186] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
45 Vulfovich M, Saba N. Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 2005;13:577-607. [DOI: 10.1517/13543784.13.6.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
46 Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol. 2002;29:413-426. [PMID: 12407507 DOI: 10.1053/sonc.2002.35237] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 3.4] [Reference Citation Analysis]
47 Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol. 2004;15:1151-1160. [PMID: 15277253 DOI: 10.1093/annonc/mdh300] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 4.1] [Reference Citation Analysis]
48 Sledge GW, Miller KD. Angiogenesis and Antiangiogenic Therapy. Current Problems in Cancer 2002;26:6-59. [DOI: 10.1016/s0147-0272(02)70005-6] [Cited by in Crossref: 20] [Article Influence: 1.0] [Reference Citation Analysis]
49 Douglas M, Reid J, Hii S, Jonsson J, Nicol D. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide: RCC, ANTI-ANGIOGENESIS AND THALIDOMIDE. BJU International 2002;89:591-5. [DOI: 10.1046/j.1464-410x.2002.02666.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
50 Marx G, Taylor J, Goldstein D. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. Intern Med J 2005;35:34-8. [PMID: 15667466 DOI: 10.1111/j.1445-5994.2004.00749.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
51 Downs LS Jr, Judson PL, Argenta PA, Ghebre R, Geller MA, Bliss RL, Boente MP, Nahhas WA, Abu-Ghazaleh SZ, Chen MD, Carson LF. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma. Cancer 2008;112:331-9. [PMID: 18058810 DOI: 10.1002/cncr.23164] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
52 Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006;26:483-530. [PMID: 16652370 DOI: 10.1002/med.20059] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 6.8] [Reference Citation Analysis]
53 Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol 2007;62:16-22. [PMID: 17208006 DOI: 10.1016/j.critrevonc.2006.11.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
54 Clark PE, Hall M, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004;63:1061-5. [DOI: 10.1016/j.urology.2004.01.035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
55 Soni S, Lee DS, DiVito J, Bui AH, DeRaffele G, Radel E, Kaufman HL. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol. 2002;24:488-491. [PMID: 12218599 DOI: 10.1097/00043426-200208000-00016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
56 Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer Treat Res 2003;115:19-72. [PMID: 12613192 DOI: 10.1007/0-306-48158-8_2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
57 Eisen T. Thalidomide in solid malignancies. J Clin Oncol 2002;20:2607-9. [PMID: 12039920 DOI: 10.1200/JCO.2002.20.11.2607] [Cited by in Crossref: 20] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Gordinier ME, Dizon DS, Weitzen S, Disilvestro PA, Moore RG, Granai CO. Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer. J Palliat Med 2007;10:61-6. [PMID: 17298255 DOI: 10.1089/jpm.2006.0083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
59 Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001;92:2364-73. [DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
60 Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis. 2001;5:479-507. [PMID: 11385973 DOI: 10.1016/s1089-3261(05)70175-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
61 Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomed Pharmacother 2002;56:115-28. [PMID: 12046682 DOI: 10.1016/s0753-3322(02)00168-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
62 Vestermark LW, Larsen S, Lindeløv B, Bastholt L. A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta Oncol 2008;47:1526-30. [PMID: 18607876 DOI: 10.1080/02841860801918521] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
63 Motzer RJ. Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol 2003;46 Suppl:S33-9. [PMID: 12850525 DOI: 10.1016/s1040-8428(03)00062-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
64 Pujol JL, Breton JL, Gervais R, Tanguy M, Quoix E, David P, Janicot H, Westeel V, Gameroff S, Genève J, Maraninchi D. Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01. JCO 2007;25:3945-51. [DOI: 10.1200/jco.2007.11.8109] [Cited by in Crossref: 114] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
65 Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol. 2008;68:242-249. [PMID: 18657433 DOI: 10.1016/j.critrevonc.2008.06.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
66 El-zahabi MA, Sakr H, El-adl K, Zayed M, Abdelraheem AS, Eissa SI, Elkady H, Eissa IH. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorganic Chemistry 2020;104:104218. [DOI: 10.1016/j.bioorg.2020.104218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
67 Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study. Cancer Immunol Immunother 2005;54:926-31. [PMID: 15906025 DOI: 10.1007/s00262-005-0677-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
68 Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12. [PMID: 15812574 DOI: 10.1007/s00345-004-0466-0] [Cited by in Crossref: 159] [Cited by in F6Publishing: 139] [Article Influence: 9.4] [Reference Citation Analysis]
69 Rosenbach M, Werth VP. Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther 2007;20:175-86. [DOI: 10.1111/j.1529-8019.2007.00132.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
70 Baidas S, Tfayli A, Bhargava P. Thalidomide: An Old Drug with New Clinical Applications. Cancer Investigation 2002;20:835-48. [DOI: 10.1081/cnv-120002498] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
71 Amare GG, Meharie BG, Belayneh YM. A drug repositioning success: The repositioned therapeutic applications and mechanisms of action of thalidomide. J Oncol Pharm Pract 2021;27:673-8. [PMID: 33249990 DOI: 10.1177/1078155220975825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Amato RJ. Thalidomide: An antineoplastic agent. Curr Oncol Rep 2002;4:56-62. [DOI: 10.1007/s11912-002-0048-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
73 Wu J, Huang D, Pang K, Hsu S, Tyring S. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 2005;153:254-73. [DOI: 10.1111/j.1365-2133.2005.06747.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 104] [Article Influence: 8.3] [Reference Citation Analysis]
74 Arrieta O, Guevara P, Tamariz J, Rembao D, Rivera E, Sotelo J. Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. Int J Exp Pathol 2002;83:99-104. [PMID: 12084046 DOI: 10.1046/j.1365-2613.2002.00219.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
75 Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M. Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. JCO 2002;20:302-6. [DOI: 10.1200/jco.2002.20.1.302] [Cited by in Crossref: 59] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
76 Ribatti D, Ponzoni M. Antiangiogenic strategies in neuroblastoma. Cancer Treat Rev 2005;31:27-34. [PMID: 15707702 DOI: 10.1016/j.ctrv.2004.09.006] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
77 Matthews S, Mccoy C. Thalidomide: A review of approved and investigational uses. Clinical Therapeutics 2003;25:342-95. [DOI: 10.1016/s0149-2918(03)80085-1] [Cited by in Crossref: 136] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
78 Amato RJ, Khan M. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2008;61:1069-73. [PMID: 17701037 DOI: 10.1007/s00280-007-0568-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
79 Noman AS, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T. Thalidomide inhibits lipopolysaccharide-induced nitric oxide production and prevents lipopolysaccharide-mediated lethality in mice. FEMS Immunol Med Microbiol 2009;56:204-11. [PMID: 19538513 DOI: 10.1111/j.1574-695X.2009.00567.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Ozols RF. Future directions in the treatment of ovarian cancer. Seminars in Oncology 2002;29:32-42. [DOI: 10.1053/sonc.2002.31594] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
81 Amato RJ, Rawat A. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study. Invest New Drugs 2006;24:171-5. [PMID: 16086096 DOI: 10.1007/s10637-005-2938-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
82 Maisey N. Antitumor necrosis factor (TNF-a) antibodies in the treatment of renal cell cancer. Cancer Invest 2007;25:589-93. [PMID: 17852116 DOI: 10.1080/07357900701359700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
83 Paley PJ. Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies. Curr Oncol Rep 2002;4:165-74. [PMID: 11822989 DOI: 10.1007/s11912-002-0078-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
84 Kumar V, Chhibber S. Thalidomide: an old drug with new action. J Chemother 2011;23:326-34. [PMID: 22233815 DOI: 10.1179/joc.2011.23.6.326] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
85 De Witte M, Shealy DJ, Nakada MT, Anderson GM. Tumor Necrosis Factor and Cancer. In: Caligiuri MA, Lotze MT, editors. Cytokines in the Genesis and Treatment of Cancer. Totowa: Humana Press; 2007. pp. 71-89. [DOI: 10.1007/978-1-59745-455-1_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Lepper ER, Ng SS, Gütschow M, Weiss M, Hauschildt S, Hecker TK, Luzzio FA, Eger K, Figg WD. Comparative molecular field analysis and comparative molecular similarity indices analysis of thalidomide analogues as angiogenesis inhibitors. J Med Chem 2004;47:2219-27. [PMID: 15084120 DOI: 10.1021/jm0304820] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
87 Catalano A, Gianni W, Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Critical Reviews in Oncology/Hematology 2004;50:101-9. [DOI: 10.1016/j.critrevonc.2003.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
88 Machida S, Saga Y, Takei Y, Mizuno I, Takayama T, Kohno T, Konno R, Ohwada M, Suzuki M. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int J Cancer 2005;114:224-9. [PMID: 15551349 DOI: 10.1002/ijc.20751] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
89 Singhal S, Mehta J. Thalidomide in Cancer: Potential Uses and Limitations. BioDrugs 2001;15:163-72. [DOI: 10.2165/00063030-200115030-00003] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 2.4] [Reference Citation Analysis]
90 Eiró N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg 2012; 4(3): 62-72 [PMID: 22530080 DOI: 10.4240/wjgs.v4.i3.62] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
91 See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest 2004;22 Suppl 2:29-44. [PMID: 15573743 DOI: 10.1081/cnv-200030119] [Cited by in Crossref: 13] [Article Influence: 0.7] [Reference Citation Analysis]
92 McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127:356-361. [PMID: 22796461 DOI: 10.1016/j.ygyno.2012.07.095] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
93 Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363:1802-1811. [PMID: 15172781 DOI: 10.1016/s0140-6736(04)16308-3] [Cited by in Crossref: 364] [Cited by in F6Publishing: 105] [Article Influence: 20.2] [Reference Citation Analysis]
94 Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas: . Current Opinion in Oncology 2001;13:261-9. [DOI: 10.1097/00001622-200107000-00009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
95 Griffiths TR, Mellon JK. Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J 2004;80:320-7. [PMID: 15192163 DOI: 10.1136/pgmj.2003.013508] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
96 Daruwalla J, Nikfarjam M, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of thalidomide on colorectal cancer liver metastases in CBA mice. J Surg Oncol 2005;91:134-40. [PMID: 16028287 DOI: 10.1002/jso.20289] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
97 Lee CP, Patel PM, Selby PJ, Hancock BW, Mak I, Pyle L, James MG, Beirne DA, Steeds S, A'hern R, Gore ME, Eisen T. Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 2006;24:898-903. [DOI: 10.1200/jco.2005.03.7309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
98 Morabito A, Sarmiento R, Bonginelli P, Gasparini G. Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Crit Rev Oncol Hematol. 2004;49:91-107. [PMID: 15012971 DOI: 10.1016/S1040-8428(03)00168-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
99 Patel PH, Kondagunta GV, Schwartz L, Ishill N, Bacik J, Deluca J, Russo P, Motzer RJ. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs 2008;26:273-6. [DOI: 10.1007/s10637-007-9107-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
100 Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 2002;20:389-93. [PMID: 12448656 DOI: 10.1023/a:1020669705369] [Cited by in Crossref: 38] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
101 Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002;95:758-65. [DOI: 10.1002/cncr.10740] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
102 Cyran CC, Sennino B, Chaopathomkul B, Fu Y, Rogut VS, Shames DM, Wendland MF, McDonald DM, Brasch RC. Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers. Eur Radiol 2009;19:121-31. [PMID: 18665367 DOI: 10.1007/s00330-008-1111-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
103 Solti M, Berd D, Mastrangelo MJ, Sato T. A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res 2007;17:225-31. [PMID: 17625452 DOI: 10.1097/CMR.0b013e32823ed0d1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
104 Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23:625-34. [PMID: 16305990 DOI: 10.1080/07357900500283101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
105 Dredge K, Marriott JB, Todryk SM, Muller GW, Chen R, Stirling DI, Dalgleish AG. Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity. J Immunol 2002;168:4914-9. [DOI: 10.4049/jimmunol.168.10.4914] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 6.1] [Reference Citation Analysis]
106 Aalamian M, Fuchs E, Gupta R, Levey DL. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urologic Oncology: Seminars and Original Investigations 2006;24:425-33. [DOI: 10.1016/j.urolonc.2005.08.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
107 Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma: . Journal of Immunotherapy 2004;27:259-64. [DOI: 10.1097/00002371-200407000-00001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
108 Lv M, Liu Y, Ma S, Yu Z. Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry 2019;11:2595-620. [DOI: 10.4155/fmc-2019-0111] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
109 Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961. [PMID: 14997189 DOI: 10.1038/sj.bjc.6601579] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
110 Noman ASM, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T. Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation. Biochemical and Biophysical Research Communications 2008;374:683-7. [DOI: 10.1016/j.bbrc.2008.07.090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
111 Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008;61:661-8. [PMID: 17589846 DOI: 10.1007/s00280-007-0521-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
112 Tempfer CB, Schultheis B, Hilal Z, Dogan A, Rezniczek GA. Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature. Oncol Lett 2017;14:3327-36. [PMID: 28927084 DOI: 10.3892/ol.2017.6578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Djordjevic G, Mozetic V, Mozetic DV, Licul V, Ilijas KM, Mustac E, Oguic R, Fuckar Z, Jonjic N. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract. 2007;203:99-106. [PMID: 17270362 DOI: 10.1016/j.prp.2006.12.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
114 Aguayo A, Patt YZ. Nonsurgical Treatment of Hepatocellular Carcinoma. Clinics in Liver Disease 2001;5:175-89. [DOI: 10.1016/s1089-3261(05)70160-4] [Cited by in Crossref: 5] [Article Influence: 0.2] [Reference Citation Analysis]
115 Jeyakumar A, Chalas E, Hindenburg A. Sustained Complete Remission in a Patient with Platinum-Resistant Ovarian Yolk Sac Tumor. Gynecologic Oncology 2001;82:578-80. [DOI: 10.1006/gyno.2001.6327] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
116 Seigne J, Antonia S, Fishman M. Novel therapies for renal cell carcinoma. Expert Opinion on Investigational Drugs 2005;10:1033-44. [DOI: 10.1517/13543784.10.6.1033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
117 Kuefer R, Autenrieth M, Herkommer K, Blum P, Merseburger A, Hofer M, Rinnab L, Gschwend J, Ringhoffer M. Translation molekularer Zusammenhänge in die klinische Anwendung: Dargestellt am Beispiel des Vascular-Endothelial-Growth-Factor- (VEGF-)Pathway. Urologe 2006;45:328-35. [DOI: 10.1007/s00120-006-1006-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
118 Teo S, Evans M, Ehrhart J, Brockman M, Allen D, Morgan M, Stirling D, Thomas S. Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules. Hum Exp Toxicol 2000;19:615-22. [DOI: 10.1191/096032700673027800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
119 Hernberg M, Virkkunen P, Bono P, Ahtinen H, Mäenpää H, Joensuu H. Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma. JCO 2003;21:3770-6. [DOI: 10.1200/jco.2003.01.536] [Cited by in Crossref: 51] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
120 Maria de Souza C, Fonseca de Carvalho L, da Silva Vieira T, Cândida Araújo E Silva A, Teresa Paz Lopes M, Alves Neves Diniz Ferreira M, Passos Andrade S, Dantas Cassali G. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomed Pharmacother 2012;66:491-8. [PMID: 22705333 DOI: 10.1016/j.biopha.2012.04.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
121 Tan TH, Pranavan G, Haxhimolla HZ, Yip D. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia-Pacific Journal of Clinical Oncology 2010;6:5-18. [DOI: 10.1111/j.1743-7563.2010.01277.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
122 Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23:1028-1043. [PMID: 15534359 DOI: 10.1200/jco.2005.01.186] [Cited by in Crossref: 282] [Cited by in F6Publishing: 82] [Article Influence: 15.7] [Reference Citation Analysis]
123 Adlard JW. Thalidomide in the treatment of cancer: . Anti-Cancer Drugs 2000;11:787-91. [DOI: 10.1097/00001813-200011000-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
124 Nathan PD, Eisen TG. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol. 2002;3:89-96. [PMID: 11902528 DOI: 10.1016/s1470-2045(02)00650-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
125 Passos GR, Camargo JA, Ferrari KL, Saad MJA, de Mattos AC, Reis LO. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment. Med Oncol 2017;35:3. [PMID: 29209984 DOI: 10.1007/s12032-017-1067-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
126 Flaherty KT. New molecular targets in melanoma. Curr Opin Oncol 2004;16:150-4. [PMID: 15075908 DOI: 10.1097/00001622-200403000-00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
127 Kindler HL. Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer 2004;45 Suppl 1:S125-7. [PMID: 15261445 DOI: 10.1016/j.lungcan.2004.04.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
128 Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85:953-8. [PMID: 11592764 DOI: 10.1054/bjoc.2001.2025] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 3.4] [Reference Citation Analysis]
129 Kumar S, Witzig TE, Rajkumar SV. Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. JCO 2004;22:2477-88. [DOI: 10.1200/jco.2004.10.127] [Cited by in Crossref: 67] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
130 Kowaliuk J, Sarsarshahi S, Hlawatsch J, Kastsova A, Kowaliuk M, Krischak A, Kuess P, Duong L, Dörr W. Translational Aspects of Nuclear Factor-Kappa B and Its Modulation by Thalidomide on Early and Late Radiation Sequelae in Urinary Bladder Dysfunction. Int J Radiat Oncol Biol Phys 2020;107:377-85. [PMID: 32035188 DOI: 10.1016/j.ijrobp.2020.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25:4542-4549. [PMID: 17925549 DOI: 10.1200/jco.2007.11.2136] [Cited by in Crossref: 158] [Cited by in F6Publishing: 80] [Article Influence: 10.5] [Reference Citation Analysis]
132 Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 2003;12:1211-25. [PMID: 12831355 DOI: 10.1517/13543784.12.7.1211] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
133 D’hondt V, Gil T, Lalami Y, Piccart M, Awada A. Will the dark sky over advanced renal cell carcinoma soon become brighter? European Journal of Cancer 2005;41:1246-53. [DOI: 10.1016/j.ejca.2004.11.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
134 Fraiman G, Ganti AK, Potti A, Mehdi S. Angiosarcoma of the small intestine: a possible role for thalidomide? Med Oncol. 2003;20:397-402. [PMID: 14716038 DOI: 10.1385/mo:20:4:397] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
135 Harshman LC, Li M, Srinivas S. The Combination of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma—Is Not the Answer. American Journal of Clinical Oncology 2008;31:417-23. [DOI: 10.1097/coc.0b013e318168ef47] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
136 Scappaticci FA. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies. JCO 2002;20:3906-27. [DOI: 10.1200/jco.2002.01.033] [Cited by in Crossref: 169] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
137 Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273-292. [PMID: 10983733 DOI: 10.2165/00003495-200060020-00003] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 3.6] [Reference Citation Analysis]
138 Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer. 2008;113:2139-2145. [PMID: 18792064 DOI: 10.1002/cncr.23805] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
139 Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322. [PMID: 15057291 DOI: 10.1038/nrc1323] [Cited by in Crossref: 550] [Cited by in F6Publishing: 481] [Article Influence: 30.6] [Reference Citation Analysis]
140 Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer 2007;97:978-85. [PMID: 17912242 DOI: 10.1038/sj.bjc.6603923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
141 Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9. [PMID: 17551310 DOI: 10.1097/01.coc.0000256104.80089.35] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
142 Keifer JA, Guttridge DC, Ashburner BP, Jr.baldwin AS. Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity. Journal of Biological Chemistry 2001;276:22382-7. [DOI: 10.1074/jbc.m100938200] [Cited by in Crossref: 344] [Cited by in F6Publishing: 78] [Article Influence: 16.4] [Reference Citation Analysis]
143 Dutcher JP, Leon L, Manola J, Friedland DM, Roth B, Wilding G. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group study. Cancer 2005;104:2392-9. [DOI: 10.1002/cncr.21473] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
144 Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther 2007;7:701-13. [PMID: 17492933 DOI: 10.1586/14737140.7.5.701] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
145 Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002;29:82-96. [PMID: 11836673 DOI: 10.1053/sonc.2002.30234] [Cited by in Crossref: 94] [Cited by in F6Publishing: 68] [Article Influence: 4.7] [Reference Citation Analysis]
146 Morabito A, Carillio G, Longo R, Gasparini G. Thalidomide Is Inactive in Heavily Pretreated Patients with Metastatic Breast Cancer: . The Cancer Journal 2005;11:248-51. [DOI: 10.1097/00130404-200505000-00012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
147 See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: Current status and future prospects. Int J Gynecol Cancer 2003;13:701-34. [DOI: 10.1111/j.1525-1438.2003.13601.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
148 Pavlick AC, Adams S, Fink MA, Bailes A. Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Investig Drugs 2003;12:1545-58. [PMID: 12943498 DOI: 10.1517/13543784.12.9.1545] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
149 Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003;22:3172-3179. [PMID: 12789293 DOI: 10.1038/sj.onc.1206457] [Cited by in Crossref: 155] [Cited by in F6Publishing: 136] [Article Influence: 8.2] [Reference Citation Analysis]
150 Rani P, Pal D, Hegde RR, Hashim SR. Acetamides: chemotherapeutic agents for inflammation-associated cancers. J Chemother 2016;28:255-65. [PMID: 26198312 DOI: 10.1179/1973947815Y.0000000060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
151 Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A. Phase II trial of thalidomide in renal-cell carcinoma. Annals of Oncology 2002;13:1029-35. [DOI: 10.1093/annonc/mdf213] [Cited by in Crossref: 83] [Cited by in F6Publishing: 69] [Article Influence: 4.2] [Reference Citation Analysis]
152 Dimopoulos MA, Eleutherakis-papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. The American Journal of Medicine 2004;117:508-15. [DOI: 10.1016/j.amjmed.2004.03.040] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 4.8] [Reference Citation Analysis]
153 Carcache de-Blanco EJ, Pandit B, Hu Z, Shi J, Lewis A, Li P. Inhibitors of NF-κB derived from thalidomide. Bioorganic & Medicinal Chemistry Letters 2007;17:6031-5. [DOI: 10.1016/j.bmcl.2007.01.088] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
154 Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009;8:235-253. [PMID: 19247306 DOI: 10.1038/nrd2792] [Cited by in Crossref: 1105] [Cited by in F6Publishing: 1039] [Article Influence: 85.0] [Reference Citation Analysis]
155 Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med 2017;123:98-104. [PMID: 28137504 DOI: 10.1016/j.rmed.2016.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
156 Harshman LC, Srinivas S. The bevacizumab experience in advanced renal cell carcinoma. Onco Targets Ther 2010;3:179-89. [PMID: 21049084 DOI: 10.2147/ott.s8157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
157 Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002;95:1629-36. [DOI: 10.1002/cncr.10847] [Cited by in Crossref: 94] [Cited by in F6Publishing: 75] [Article Influence: 4.7] [Reference Citation Analysis]
158 Khan ZH, Simpson EJ, Cole AT, Holt M, Macdonald I, Pye D, Austin A, Freeman JG. Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass: OESOPHAGEAL CANCER AND CACHEXIA. Alimentary Pharmacology & Therapeutics 2003;17:677-82. [DOI: 10.1046/j.1365-2036.2003.01457.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 3.5] [Reference Citation Analysis]
159 Hwu W, Krown SE, Menell JH, Panageas KS, Merrell J, Lamb LA, Williams LJ, Quinn CJ, Foster T, Chapman PB, Livingston PO, Wolchok JD, Houghton AN. Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma. JCO 2003;21:3351-6. [DOI: 10.1200/jco.2003.02.061] [Cited by in Crossref: 114] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
160 Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemother Pharmacol. 2007;59:165-174. [PMID: 16736151 DOI: 10.1007/s00280-006-0255-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
161 Mross K. Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials. Drug Resistance Updates 2000;3:223-35. [DOI: 10.1054/drup.2000.0150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
162 Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 2000;14:901-18. [DOI: 10.1053/beog.2000.0134] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
163 Hassan I, Dorjay K, Anwar P. Thalidomide in dermatology: revisited. Indian J Dermatol 2015;60:213. [PMID: 25814738 DOI: 10.4103/0019-5154.152580] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
164 Lutzky J, Weber R, Nunez Y, Gillett M, Spitler L. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. J Immunother 2009;32:79-85. [PMID: 19307996 DOI: 10.1097/CJI.0b013e31818c8aaf] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
165 Guntinas-lichius O, Wittekindt C. The Role of Growth Factors for Disease and Therapy in Diseases of the Head and Neck. DNA and Cell Biology 2003;22:593-606. [DOI: 10.1089/104454903322405473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
166 Chan JK, Manuel MR, Ciaravino G, Cheung MK, Husain A, Teng NN. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol 2006;103:919-23. [PMID: 16828852 DOI: 10.1016/j.ygyno.2006.05.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
167 Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 2008;179:81-6; discussion 86. [PMID: 17997441 DOI: 10.1016/j.juro.2007.08.127] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 7.3] [Reference Citation Analysis]
168 Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M. Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 2003;43:309-19. [PMID: 12600436 DOI: 10.1016/s0302-2838(03)00005-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
169 Li Q, Liu Y, Yu Y. Antiangiogenic therapy for primitive neuroectodermal tumor with thalidomide: A case report and review of literature. Medicine (Baltimore) 2017;96:e9272. [PMID: 29390485 DOI: 10.1097/MD.0000000000009272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
170 Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F. Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev. 2006;32:437-444. [PMID: 16870349 DOI: 10.1016/j.ctrv.2006.06.002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
171 Stebbing J, Gore M. The current status of interferon-α treatment in advanced renal cancer: INTERFERON-α IN ADVANCED RENAL CANCER. BJU International 2001;87:599-601. [DOI: 10.1046/j.1464-410x.2001.02140.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
172 Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 2010;116:146-54. [PMID: 19862820 DOI: 10.1002/cncr.24686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
173 Yun YR, Won JE, Jeon E, Lee S, Kang W, Jo H, Jang JH, Shin US, Kim HW. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng 2010;2010:218142. [PMID: 21350642 DOI: 10.4061/2010/218142] [Cited by in Crossref: 270] [Cited by in F6Publishing: 252] [Article Influence: 22.5] [Reference Citation Analysis]
174 Nathan PD, Gore ME, Eisen TG. Unexpected Toxicity of Combination Thalidomide and Interferon Alfa-2a Treatment in Metastatic Renal Cell Carcinoma. JCO 2002;20:1429-30. [DOI: 10.1200/jco.2002.20.5.1429] [Cited by in Crossref: 45] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
175 Marriott JB, Clarke IA, Dredge K, Muller G, Stirling D, Dalgleish AG. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002;130:75-84. [PMID: 12296856 DOI: 10.1046/j.1365-2249.2002.01954.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 5.8] [Reference Citation Analysis]
176 Ribatti D, Vacca A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 2005;19:1525-31. [PMID: 15973447 DOI: 10.1038/sj.leu.2403852] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
177 Capitosti SM, Hansen TP, Brown ML. Facile synthesis of an azido-labeled thalidomide analogue. Org Lett 2003;5:2865-7. [PMID: 12889894 DOI: 10.1021/ol034906w] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
178 Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006;42:2318-25. [PMID: 16899362 DOI: 10.1016/j.ejca.2006.05.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
179 Singhal S, Mehta J. Thalidomide in cancer. Biomedicine & Pharmacotherapy 2002;56:4-12. [DOI: 10.1016/s0753-3322(01)00146-9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
180 Ponomaryov Y, Krasikova V, Lebedev A, Chernyak D, Varacheva L, Chernobroviy A. Scalable and green process for the synthesis of anticancer drug lenalidomide. Chem Heterocycl Comp 2015;51:133-8. [DOI: 10.1007/s10593-015-1670-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Mcmeekin DS, Sill MW, Darcy KM, Stearns-kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study. Gynecologic Oncology 2007;106:596-603. [DOI: 10.1016/j.ygyno.2007.05.013] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
182 Abramson N, Stokes PK, Luke M, Marks AR, Harris JM. Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide. J Clin Oncol 2002;20:1147-9. [PMID: 11844842 DOI: 10.1200/JCO.2002.20.4.1147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
183 Ansell A, Jerhammar F, Ceder R, Grafström R, Grénman R, Roberg K. Matrix metalloproteinase-7 and -13 expression associate to cisplatin resistance in head and neck cancer cell lines. Oral Oncol. 2009;45:866-871. [PMID: 19442568 DOI: 10.1016/j.oraloncology.2009.02.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
184 Redman BG, Chang AE. Advanced renal cell carcinoma. Curr Treat Options Oncol 2000;1:417-22. [PMID: 12057149 DOI: 10.1007/s11864-000-0069-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
185 Deplanque G, Harris A. Anti-angiogenic agents. European Journal of Cancer 2000;36:1713-24. [DOI: 10.1016/s0959-8049(00)00149-0] [Cited by in Crossref: 68] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
186 Kumar S, Witzig TE, Rajkumar SV. Thalidomide as an anti-cancer agent. J Cell Mol Med 2002;6:160-74. [PMID: 12169202 DOI: 10.1111/j.1582-4934.2002.tb00184.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
187 Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia 2009;11:529-41. [PMID: 19484142 DOI: 10.1593/neo.09112] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
188 Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-95. [PMID: 19445576 DOI: 10.1586/era.09.25] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 9.1] [Reference Citation Analysis]
189 Belo AV, Ferreira MA, Bosco AA, Machado RD, Andrade SP. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation. 2001;25:91-96. [PMID: 11321364 DOI: 10.1023/a:1007114404953] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
190 Li WW. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging. Academic Radiology 2000;7:800-11. [DOI: 10.1016/s1076-6332(00)80629-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
191 Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 2009;115:5228-36. [PMID: 19728370 DOI: 10.1002/cncr.24576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
192 Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008;49:1238-1245. [PMID: 18452080 DOI: 10.1080/10428190802005191] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
193 Lee SM, James L, Buchler T, Snee M, Ellis P, Hackshaw A. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 2008;59:364-8. [PMID: 17920723 DOI: 10.1016/j.lungcan.2007.08.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
194 Laduca JR, Gaspari AA. TARGETING TUMOUR NECROSIS FACTOR ALPHA. Dermatologic Clinics 2001;19:617-35. [DOI: 10.1016/s0733-8635(05)70304-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
195 Jatoi A, Loprinzi CL. An update: cancer-associated anorexia as a treatment target: . Current Opinion in Clinical Nutrition and Metabolic Care 2001;4:179-82. [DOI: 10.1097/00075197-200105000-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
196 Majumdar S, Lamothe B, Aggarwal BB. Thalidomide Suppresses NF-κB Activation Induced by TNF and H 2 O 2 , But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J Immunol 2002;168:2644-51. [DOI: 10.4049/jimmunol.168.6.2644] [Cited by in Crossref: 126] [Cited by in F6Publishing: 108] [Article Influence: 6.3] [Reference Citation Analysis]
197 Gadducci A, Sergiampietri C, Guiggi I. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option. Gynecological Endocrinology 2013;29:811-6. [DOI: 10.3109/09513590.2013.801446] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
198 Kut C, Mac Gabhann F, Popel AS. Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. Br J Cancer. 2007;97:978-985. [PMID: 17912242 DOI: 10.1038/sj.bjc.6603923] [Cited by in Crossref: 166] [Cited by in F6Publishing: 153] [Article Influence: 11.1] [Reference Citation Analysis]
199 Hwu W, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ, Houghton AN. Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial. JCO 2002;20:2610-5. [DOI: 10.1200/jco.2002.09.034] [Cited by in Crossref: 53] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
200 Zhang ZL, Liu ZS, Sun Q. Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice. World J Gastroenterol 2005; 11(2): 216-220 [PMID: 15633219 DOI: 10.3748/wjg.v11.i2.216] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
201 Gerecitano J, O’connor OA. Novel Small Molecules in the Treatment of Lymphomas. In: Leonard JP, Coleman M, editors. Hodgkin’s and Non-Hodgkin’s Lymphoma. Boston: Springer US; 2006. pp. 413-60. [DOI: 10.1007/978-0-387-29346-2_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
202 Fazzi P, Manni E, Cristofani R, Cei G, Piazza S, Calabrese R, Antonelli A, Siciliano G, Barachini P, Carpi A. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomedicine & Pharmacotherapy 2012;66:300-7. [DOI: 10.1016/j.biopha.2012.03.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
203 Riedel RF, Crawford J, Dunphy F, Herndon Ii JE, Garst J, Kelley MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer 2006;54:431-2. [DOI: 10.1016/j.lungcan.2006.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
204 DE Campos CB, Lavalle GE, Monteiro LN, Pêgas GRA, Fialho SL, Balabram D, Cassali GD. Adjuvant Thalidomide and Metronomic Chemotherapy for the Treatment of Canine Malignant Mammary Gland Neoplasms. In Vivo 2018;32:1659-66. [PMID: 30348731 DOI: 10.21873/invivo.11429] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
205 Dutcher JP. Angiogenesis and melanoma. Curr Oncol Rep 2001;3:353-8. [DOI: 10.1007/s11912-001-0089-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
206 Steins MB, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J, Kessler T, Buechner T, Berdel WE, Mesters RM. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002;99:834-9. [DOI: 10.1182/blood.v99.3.834] [Cited by in Crossref: 65] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
207 McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD; Gynecologic Oncology Group. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105:508-16. [PMID: 17306350 DOI: 10.1016/j.ygyno.2007.01.019] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
208 Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer 2010;116:424-31. [PMID: 19918923 DOI: 10.1002/cncr.24739] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
209 Sebens S, Arlt A, Schäfer H. NF-κ B as a Molecular Target in the Therapy of Pancreatic Carcinoma. Pancreatic Cancer. Berlin: Springer Berlin Heidelberg; 2008. pp. 151-64. [DOI: 10.1007/978-3-540-71279-4_17] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
210 Noman ASM, Koide N, Hassan F, I.-e-khuda I, Dagvadorj J, Tumurkhuu G, Islam S, Naiki Y, Yoshida T, Yokochi T. Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-α production via down-regulation of MyD88 expression. Innate Immun 2009;15:33-41. [DOI: 10.1177/1753425908099317] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
211 Stoutenburg JP, Schrope B, Kaufman HL. Adjuvant therapy for malignant melanoma. Expert Review of Anticancer Therapy 2014;4:823-35. [DOI: 10.1586/14737140.4.5.823] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]